Kumar P, Rodriguez-French A, Thompson M, Tashima K, Williams V, Wannamaker P, Shaefer M; Conference on Retroviruses and Opportunistic Infections.
9th Conf Retrovir Oppor Infect Feb 24 28 2002 Wash State Conv Trade Cent Seattle Wash Conf Retrovir Oppor Infect 9th 2002 Seattle Wash. 2002 Feb 24-28; 9: abstract no. 33.
Georgetown Univ. Med. Ctr., Washington, DC
BACKGROUND: Hyperlipidemia is a common side effect of HAART therapy. The effect that non-PI-containing regimens have on the development of hyperlipidemia and fat redistribution (FR) is not fully known. Our objectives were to evaluate changes in fasting metabolic parameters, clinical evaluations of FR, safety, and efficacy in subjects treated with COM/ABC vs COM/NFV vs d4T/3TC/NFV for 96 weeks.METHODS: 258 non-diabetic, ART-naive subjects with CD4 >50 cells/mm(3) were randomized 1:1:1. Evaluations consisted of fasting lipid profiles and other clinical evaluations of FR at baseline through 96 weeks. Results were compared in an analysis of covariance model adjusting for baseline.RESULTS: A planned interim analysis at 48 weeks (50% female, 40% African American, 37% Hispanic) indicate significant increases in LDL and total cholesterol in both of the PI-containing arms compared to the COM/ABC arm. [table: see text] .CONCLUSIONS: These 48-week results indicate that therapy with COM/ABC has comparable virologic and immunologic efficacy with a more favorable lipid profile as compared to PI-containing regimens. Gender differences will be presented.
Publication Types:
Keywords:
- Antiretroviral Therapy, Highly Active
- Combivir
- Dideoxynucleosides
- Drug Combinations
- FR dental filling
- Female
- Lamivudine
- Nelfinavir
- Prospective Studies
- Stavudine
- Zidovudine
- abacavir
Other ID:
UI: 102263786
From Meeting Abstracts